Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A physician-initiated double-blind, randomised, placebo-controlled , phase 2 study evaluating the efficacy and safety of inhibition of NADPH Oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion

Trial Profile

A physician-initiated double-blind, randomised, placebo-controlled , phase 2 study evaluating the efficacy and safety of inhibition of NADPH Oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Setanaxib (Primary)
  • Indications Diabetic nephropathies; Renal fibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Dec 2019 According to a GenKyoTex media release, 13 patients have already completed the full 48-week treatment and no safety signals have been identified.
    • 03 Dec 2019 According to a GenKyoTex media release, the trial protocol has amended to increase the dose to 400 mg BID based on the positive efficacy and safety results from phase 2 trial of setanaxib in primary biliary cholangitis.
    • 03 Dec 2019 According to a GenKyoTex media release, the principal investigators leading this trial with agreement from Genkyotex has decided to to expand the investigational network by adding centers in Germany, Denmark and New Zealand and New Zealand will be the first country to add centers and will be followed by Germany and Denmark.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top